Thymosin-a 1 for treatment of chronic hepatitis B

ABSTRACT

A study on 56 patients with chronic hepatitis B who were divided into 2 groups study group and control group. The study group including 31 patients was treated with Thymosin-α1 1.6mg/day, twice a week for 6 months. The control group with 25 patients of same clinical data was treated with common liver-protective drugs. Both groups were monitored and assessed after 24 months. The results showed that the study group with treatment of Thymosin-α1 is better than control one in all aspects of ALT normalization, sero-conversion and decrease of HBV-DNA<5 copies/ml